Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
03/2003
03/27/2003WO2002094263A3 Caspase inhibitors and uses thereof
03/27/2003WO2002034201A3 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
03/27/2003WO2002026219A3 Otic microbial combinations for treatment of animals with ruptured tympanic membrane
03/27/2003WO2002012340A3 Transporters and ion channels
03/27/2003US20030060629 Pyrazine derivatives as modulators of tyrosine kinases
03/27/2003US20030060627 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives
03/27/2003US20030060619 Antibody for use in the disgnosis and treatment of kidney, urogenital, and sex disorders
03/27/2003US20030060511 Method for treatment of ocular hypertension and glaucoma
03/27/2003US20030060510 Administering to the patient a compound capable of reducing glutamate-induced retinal cell migration in a concentration effective to reduce such migration
03/27/2003US20030060497 Use of indole Mannich bases in the production of medicaments that are used to treat pain
03/27/2003US20030060492 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
03/27/2003US20030060491 Bicyclic aromatic compounds
03/27/2003US20030060466 Such as 6-(4-(4-Fluoro-phenyl)-piperazin-1-yl)-2-methyl-5-nitro-3-(2,2,2-trifluoro -ethyl)-3H-pyrimidin-4-one, which are metabotropic glutamate receptor antagonists useful in treating psychological disorders
03/27/2003US20030060410 Use of HMG fragments as anti-inflammatory agents
03/27/2003US20030060401 Genetic engineered drug
03/27/2003US20030059916 IRAK-4: compositions and methods of use
03/27/2003US20030059868 Retinal cell lines with extended life-span and their applications
03/27/2003US20030059862 Antibodies against tumor necrosis factor delta (APRIL)
03/27/2003US20030059796 Detecting genes associated with controlling angiogenesis; obtain and culture endothelial cells, isolate ribonucleic acids, amplified or reduced concentrations of preferenial ribonucleic acids indicate association with angiogenesis
03/27/2003US20030059423 Method for treating symptoms of diabetes
03/27/2003US20030059417 Methods and compositions for diagnosing and treating disorders involving angiogenesis
03/27/2003CA2461065A1 Transductin-1 and transductin-2 and applications to hereditary deafness
03/27/2003CA2460808A1 Immune response associated proteins
03/27/2003CA2460460A1 Fermentation product of cryptoporus volvatus and its preparation method and use
03/27/2003CA2460360A1 Systematical administration of some oxazolidinones, e.g. linezolid, for the treatment for ocular infections
03/27/2003CA2460358A1 Hydroxyfattysulfonic acid analogs
03/27/2003CA2460263A1 Hydroxyeicosenoic acid analogs
03/27/2003CA2459454A1 Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
03/26/2003EP1295939A1 Insulin-like growth factor binding protein
03/26/2003EP1294924A2 Method for identifying medically valuable active substances
03/26/2003EP1294895A2 Calpain protease 12
03/26/2003EP1294874A2 Cd154 variants and uses thereof
03/26/2003EP1294868A2 Adenylyl and guanylyl cyclases
03/26/2003EP1294765A2 Il-17 molecules and uses thereof
03/26/2003EP1294752A2 Angiogenesis-modulating compositions and uses
03/26/2003EP1294740A2 Chemically-modified antimicrobial peptides, compositions and methods of production and use
03/26/2003EP1294725A2 Multicyclic compounds and the use thereof as inhibitors of parp, vegfr2 and mlk3 enzymes
03/26/2003EP1294721A1 Cyclic gmp-specific phosphodiesterase inhibitors
03/26/2003EP1294717A2 A thiazine oxazolidinone
03/26/2003EP1294700A2 Benzhydryl derivatives
03/26/2003EP1294691A1 Serine protease inhibitors
03/26/2003EP1294690A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
03/26/2003EP1294391A2 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
03/26/2003EP1294390A2 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
03/26/2003EP1200431B1 Quinuclidine derivatives and their use as muscarinic m3 receptors ligands
03/26/2003EP1105384B1 Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors
03/26/2003EP0956038B1 Morphogen peptide-induced regeneration of sense perceptory tissues
03/26/2003CN1406237A Novel benzosultam oxazolidinone antibacterial agents
03/26/2003CN1406230A 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
03/26/2003CN1406229A Pyrimidine compounds
03/26/2003CN1406225A Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
03/26/2003CN1406134A Drugs for ameliorating retinal function
03/26/2003CN1406132A Method for treating or inhibiting cellular injury or cell death
03/26/2003CN1406127A Thiazolium compounds and treatments of disorders associated with protein aging
03/26/2003CN1405314A Cryptoporus volvatus fermented product, and its preparation method and application
03/26/2003CN1103775C Vitronectin receptor antagonists, their preparation and use
03/26/2003CN1103772C Novel 2,3-disubstituted-4 (3H)-quinazolinone
03/25/2003US6538149 Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo [1,2-g]chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
03/25/2003US6538103 Anti-angiogenic agents; kringle 1; use treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, arteriosclerotic plaque formation
03/25/2003US6538021 Method for producing luteolin and luteolin derivatives
03/25/2003US6538009 Pyrazole derivatives as anti-inflammatory/analgesic agents
03/25/2003US6537984 Contacting a targeted solid tumor cell population with a combination of a vinca alkaloid selected from vinblastine, vincristine, vinorelbine, and a triptolide in combination dosage to reduce the targeted tumor cell population
03/25/2003US6537808 Preservation of eye tissues in culture; obtain tissue, mix with nutrient broth, monitor stability of sample and cultures
03/25/2003US6537581 Compositions and methods for treating eye discomfort
03/25/2003US6537573 Combination dosage form comprising cetirizine and pseudoephedrine
03/25/2003US6537545 Use of corneal hardening agents in enzymeorthokeratology
03/25/2003CA2224093C Human vascular endothelial growth factor 2
03/21/2003WO2002026702A1 Phenoxyphenyl alkane sulfonates
03/21/2003CA2423171A1 Phenoxyphenyl alkane sulfonates
03/20/2003WO2003023404A1 A method of diagnosis and treatment and agents useful for same
03/20/2003WO2003022877A1 Crystal structure of baff, and use thereof in drug design
03/20/2003WO2003022856A1 Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
03/20/2003WO2003022842A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
03/20/2003WO2003022814A1 Indole derivatives
03/20/2003WO2003022813A1 Indole derivatives, process for producing the same and drugs containing the same as the active ingredient
03/20/2003WO2003022309A1 Remedies for allergic diseases
03/20/2003WO2003022291A1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
03/20/2003WO2003022277A1 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
03/20/2003WO2003022276A1 Aryl substituted pyridinecarboxamides and their use as sodium channel blockers
03/20/2003WO2003022271A1 Lymphocytic activation inhibitor and remedial agent for autoimmune disease
03/20/2003WO2003022266A1 Hypoestoxides, derivatives and agonists thereof for use as inhibitors of angiongenesis
03/20/2003WO2003022192A1 Eustachian tube stent
03/20/2003WO2002079404A3 Cytoskeleton-associated proteins
03/20/2003WO2002050255A3 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
03/20/2003WO2002046189A3 Aryl ether substituted imidazoquinolines
03/20/2003WO2002030444A3 Plasminogen activator to prevent corneal and subepithelial haze after laser vision correction surgery
03/20/2003WO2002020736A3 Proteases
03/20/2003WO2002018445A9 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
03/20/2003WO2001087913A9 Method for treating retinal degeneration with purinergic receptor agonists
03/20/2003US20030055260 Il-8 receptor antagonists
03/20/2003US20030055258 New crystal modification of torasemide
03/20/2003US20030055248 Il-8 receptor antagonists
03/20/2003US20030055113 Copper chelators for treating ocular inflammation
03/20/2003US20030055102 For therapy of allergic or inflammatory disorders of the eye and nose
03/20/2003US20030055098 Method of treatment
03/20/2003US20030055091 Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators
03/20/2003US20030055088 Aryl substituted pyridines and the use thereof
03/20/2003US20030055080 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
03/20/2003US20030055073 Remedies for sjoegren's syndrome
03/20/2003US20030055054 CXCR3 antagonists
1 ... 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 ... 531